![\"STING](\"https:\/\/onlinelibrary.wiley.com\/cms\/asset\/1987877f-4783-4381-ac4b-f664f995aaa9\/eji70212-gra-0001-m.png\")
<\/p>\n<\/p>\n
Our study reveals that STING activation in dendritic cells using cGAMP-VLP enhances CD8+<\/sup> T cell recognition of live tumor cells by inducing type I interferon-dependent upregulation of MHC-I on tumor cells in vitro. In vivo, cGAMP-VLP boosts antitumor immunity even in cGAS-deficient tumors, thereby improving the efficacy of immune checkpoint blockade. These findings uncover a previously underappreciated axis between dendritic-cell STING signaling and tumor immunogenicity, with important implications for STING-targeted cancer immunotherapy.<\/p>\n <\/p>\n The stimulator of interferon genes (STING) pathway is a key regulator of antitumor immunity. Activation of STING by the natural agonist 2\u20323\u2032-cyclic GMP-AMP (cGAMP) induces type I interferon and promotes CD8+<\/sup> T cell responses against tumors. However, how type I interferon modulates tumor cell recognition by T cells remains unclear. Here, using a co-culture model and virus-like particles encapsulating cGAMP (cGAMP-VLP), we show that STING activation in dendritic cells enhances CD8+<\/sup> T cell recognition of live tumor cells through type I interferon signaling. This effect is independent of enhanced cross-presentation of soluble or tumor-associated antigens. Instead, type I interferon produced downstream of STING signaling drives MHC-I upregulation on tumor cells, which is required for T cell activation. In vivo, host STING activation with cGAMP-VLP improves the efficacy of immune checkpoint blockade, particularly in tumors lacking cGAS. Together, these findings identify a transcellular mechanism whereby STING activation in dendritic cells increases tumor cell MHC-I expression to enhance CD8+<\/sup> T cell-mediated tumor recognition.<\/p>","protected":false},"excerpt":{"rendered":" Our study reveals that STING activation in dendritic cells using cGAMP-VLP enhances CD8+ T cell recognition of live tumor cells by inducing type I interferon-dependent upregulation of MHC-I on tumor cells in vitro. In vivo, cGAMP-VLP boosts antitumor immunity even in cGAS-deficient tumors, thereby improving the efficacy of immune checkpoint blockade. These findings uncover a … Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[112,42],"tags":[],"class_list":["post-65579","post","type-post","status-publish","format-standard","hentry","category-european-journal-of-immunology","category-publicaciones"],"_links":{"self":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/65579","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/comments?post=65579"}],"version-history":[{"count":0,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/65579\/revisions"}],"wp:attachment":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/media?parent=65579"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/categories?post=65579"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/tags?post=65579"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}ABSTRACT<\/h2>\n